CLEVELAND, March 11 /PRNewswire/ -- ChanTest, the leading provider of ion channel testing services for drug discovery and development customers, will feature the latest in its expanding line of services in booth 2504 at the Society of Toxicology conference March 17-20, in Seattle, Washington. New FDA Critical Path safety profiling tools include the Cardiac Channel Panel(TM) and Brain Channel Panel(TM), which ChanTest designed to complement the FDA and ICH S7A safety guidance, as well as the Pain/Inflammation and Epilepsy Channel Panels for profiling by therapeutic target. ChanTest has validated the panels against the "gold standard" manual patch clamp to ensure that results from early screens will correlate during the GLP studies that are required for IND submission.
According to Dr. Arthur (Buzz) Brown, founder and CEO of ChanTest, "At ChanTest, we've designed our comprehensive range of ion channel assays, follow-up models, and consultation services to give customers the early answers they need to identify the most-promising drug targets, and eliminate those that could be harmful - before they invest millions on clinical trials. ChanTest is the most experienced ion channel services company in the world. Our scientific team is dedicated to providing the individual attention customers need to move their project successfully through the IND process. We work closely with customers worldwide to design a testing program that meets their drug discovery, safety, regulatory, and budgetary goals. Then, we use the latest screening techniques and proprietary assays to deliver fast, accurate, and reliable results. We specialize in ion channel screening. Customers count on ChanTest because we don't just deliver raw data - our ion channel experts tell customers what the results mean."
ChanTest scientists were the first to prove hERG as the target for adverse cardiac events linked to non-cardiac drugs: Seldane (terfenadine), Propulsid (cisapride), and Nizoral (ketoconazole), and ChanTest pioneered the development of functional, cell-based ion channel testing as a means to predict cardiac side effects produced by non-cardiac drugs. Such testing is now a standard component of regulatory submissions prior to the approval of drugs for use in humans. ChanTest is committed to innovation, and is leading the next major advance in ion channel research and services with a $10 million program to develop the world's most extensive library or catalog of ion channels. ChanTest's expert electrophysiologists fully validate the ion channels for interrogation with functional, pharmacological, and biochemical assays.
About ChanTest
The preeminent ion channel services company, ChanTest serves its drug discovery and development customers with GLP safety and automated screening assays using its library of ion channel-expressing cell lines - the most comprehensive in the world. Since its inception in 1998, ChanTest has tested more than 12,000 compounds for more than 250 global pharmaceutical and biotech companies - helping them to achieve their drug safety and discovery goals. ChanTest works in partnership with customers to speed the drug-development process, save time and money, and ultimately - to help make better, safer drugs. Because of ChanTest's seminal role in this field, along with the company's uncompromising commitment to quality, ChanTest was named "most trusted fee-for-service provider" for ion channel screening in the HTStec Ion Channel Trends Survey for two years in a row. ChanTest is based in Cleveland, Ohio. For more information, please visit www.chantest.com.
CONTACT: Robert D. Schultek, ChanTest, +1-216-332-1665 x108, or Cell,
+1-216-272-4449, rschultek@chantest.com
Web site: http://www.chantest.com/
